GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) » Definitions » ROC %

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) ROC % : 5.08% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chengdu Olymvax Biopharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Chengdu Olymvax Biopharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was 5.08%.

As of today (2025-04-07), Chengdu Olymvax Biopharmaceuticals's WACC % is 11.55%. Chengdu Olymvax Biopharmaceuticals's ROC % is 3.01% (calculated using TTM income statement data). Chengdu Olymvax Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Chengdu Olymvax Biopharmaceuticals ROC % Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Olymvax Biopharmaceuticals ROC % Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.05 27.50 5.86 1.26 2.79

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.97 -16.00 10.60 11.69 5.08

Chengdu Olymvax Biopharmaceuticals ROC % Calculation

Chengdu Olymvax Biopharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=37.94 * ( 1 - 29.51% )/( (833.936 + 1081.937)/ 2 )
=26.743906/957.9365
=2.79 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1612.606 - 416.599 - ( 362.071 - max(0, 476.219 - 931.19+362.071))
=833.936

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1807.043 - 483.447 - ( 241.659 - max(0, 595.594 - 908.144+241.659))
=1081.937

Chengdu Olymvax Biopharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=71.712 * ( 1 - 24.23% )/( (1058.096 + 1081.937)/ 2 )
=54.3361824/1070.0165
=5.08 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1707.578 - 380.021 - ( 269.461 - max(0, 483.828 - 899.689+269.461))
=1058.096

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1807.043 - 483.447 - ( 241.659 - max(0, 595.594 - 908.144+241.659))
=1081.937

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Olymvax Biopharmaceuticals  (SHSE:688319) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Chengdu Olymvax Biopharmaceuticals's WACC % is 11.55%. Chengdu Olymvax Biopharmaceuticals's ROC % is 3.01% (calculated using TTM income statement data). Chengdu Olymvax Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Chengdu Olymvax Biopharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Chengdu Olymvax Biopharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Olymvax Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
Executives
Chen Dao Yuan Core technical personnel
Li Hong Guang Core technical personnel
Fan Shao Wen Directors, senior managers
Ma Heng Jun senior management
Wu Wei senior management
Fan Fan Director
Chen Ai Min Director
Tan Yong senior management
Lu Lu Director
Yu Yun Hui Director
Zhang Li Ying Core technical personnel
Chen Ke Ping Core technical personnel
Wu Qiang Core technical personnel
Yang Feng Core technical personnel

Chengdu Olymvax Biopharmaceuticals Headlines

No Headlines